Related Experiment Video
Updated: Feb 13, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway
Zhong Lei1,2,3, Huijie Duan4,5, Tengfei Zhao1,2
1Department of orthopedics Research Institute, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, Zhejiang, China.
Abstract:
Osteosarcoma (OS) is the most common primary malignant bone tumor mainly occurring in children and adolescents. In past decades, studies revealed that PARK2 was a vital tumor suppressor gene in many malignant solid tumors. However, the role of PARK2 in OS remains largely unclear. Therefore, we assessed PARK2 expression in OS tissue and adjacent non-tumor tissues by immunohistochemical (IHC) analysis, and evaluated PARK2 mRNA expression in OS cell lines by real-time PCR analysis. The HOS and U2OS cell lines were employed to establish a PARK2 overexpression model. Using this model, we investigated the potential role of PARK2 in OS and explored the underlying molecular mechanisms. Our study showed PARK2 was downregulated in OS tissue and cell lines, which was significantly associated with higher tumor stage (P < 0.05). Overexpression of PARK2 arrested the cell cycle, inhibited cell proliferation, migration, and invasion, induced cell apoptosis, and reduced tube formation in vitro. Moreover, overexpression of PARK2 significantly suppressed tumor growth and angiogenesis in vivo. Additionally, PARK2 negatively regulated OS development through the JAK2/STAT3/VEGF pathway. Our findings demonstrate that PARK2 is a tumor suppressor gene that may negatively affect OS growth and angiogenesis via partly inhibiting the JAK2/STAT3/VEGF signaling pathway.
Insights
PARK2 acts as a tumor suppressor in osteosarcoma (OS), a common bone cancer. Downregulation of PARK2 correlates with advanced tumor stage, and its restoration inhibits OS cell growth, migration, and tumor development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Osteosarcoma (OS) is the most prevalent primary bone malignancy in children and adolescents.
- The tumor suppressor gene PARK2 is implicated in various solid tumors, but its function in OS is not well understood.
Purpose of the Study:
- To investigate the expression and role of PARK2 in osteosarcoma.
- To explore the molecular mechanisms underlying PARK2's function in OS progression.
Main Methods:
- Immunohistochemical (IHC) analysis of PARK2 expression in OS tissues and adjacent non-tumor tissues.
- Real-time PCR to evaluate PARK2 mRNA levels in OS cell lines.
- Establishment of a PARK2 overexpression model in HOS and U2OS cell lines.
- In vitro assays for cell cycle, proliferation, migration, invasion, and tube formation.
- In vivo studies to assess tumor growth and angiogenesis.
Main Results:
- PARK2 expression was significantly downregulated in OS tissues and cell lines, correlating with higher tumor stage.
- PARK2 overexpression inhibited OS cell proliferation, migration, invasion, and tube formation, while inducing apoptosis.
- In vivo, PARK2 overexpression suppressed tumor growth and angiogenesis.
- PARK2 negatively regulated OS development via the JAK2/STAT3/VEGF pathway.
Conclusions:
- PARK2 functions as a tumor suppressor gene in osteosarcoma.
- PARK2 inhibits OS growth and angiogenesis, partly by downregulating the JAK2/STAT3/VEGF signaling pathway.
Related Concept Videos
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

